Nectar Lifesciences Limited has successfully completed the slump sale of its active pharmaceutical ingredients (API) and formulations business to Cephi Lifesciences Private Limited. The transaction, which also included an asset sale to the same purchaser, was finalized on November 10, 2025, following the execution of business transfer and asset purchase agreements on July 07, 2025.

Transaction Details

The completion of this significant corporate action includes all deliverables as outlined in the respective agreements. This move represents a substantial shift in Nectar Lifesciences' business structure and operations.

Management Changes

As part of this transition, several key management changes have taken place:

All four individuals have ceased their employment with Nectar Lifesciences and have been transferred to Cephi Lifesciences Private Limited, effective November 10, 2025, in accordance with the terms of the business transfer agreement.

Continued Involvement

It's worth noting that Dr. Surulichamy Senthilkumar, while resigning from his position as Whole-time Director, will continue to serve as a Non-Executive Director of Nectar Lifesciences Limited. However, this role will be without remuneration or sitting fees until further notice.

Implications

This transaction marks a significant milestone for Nectar Lifesciences, potentially reshaping its business focus and operational structure. The transfer of key personnel to Cephi Lifesciences, along with the API and formulations business, suggests a strategic realignment for both companies involved in the deal.

As the pharmaceutical landscape continues to evolve, this move may have implications for Nectar Lifesciences' future direction and market positioning. Stakeholders will likely be watching closely to see how this transaction impacts the company's performance and strategy in the coming months.

Nectar Lifesciences Limited, a prominent player in the pharmaceutical industry, has announced a significant change in its senior management. Mr. Ashok Kumar, the company's Vice President of Exports, has tendered his resignation, effective November 9, 2025.

Resignation Details

According to the company's official communication to the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), Mr. Kumar cited personal reasons for his departure. In his resignation letter addressed to CEO Mr. Amit Chadah, Kumar requested immediate relief from his responsibilities.

Corporate Disclosure

In compliance with the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations, Nectar Lifesciences promptly informed the stock exchanges about this senior management change. The company provided the following details as required by the LODR Regulations:

Additional Corporate Updates

In a separate announcement, Nectar Lifesciences also notified the stock exchanges about an upcoming board meeting. The meeting is scheduled for Friday, November 14, 2025, to consider and approve the Unaudited Financial Results for the quarter and half year ended on September 30, 2025, among other matters.

This management change and the upcoming financial review highlight the company's commitment to transparency and adherence to regulatory requirements. Investors and stakeholders will be keenly watching how these developments might impact Nectar Lifesciences' future strategies, particularly in its export operations.